Uncategorized
Fixed combination dosing lowers IOP more than individual components
CORONADO, Calif. — An “astounding” 40% reduction in IOP achieved with one drug given once a day was achieved in 35% of patients taking a fixed-dose combination of netarsudil and latanoprost, according to a speaker here. Sanjay Asrani, MD, updated colleagues at the American Glaucoma Society meeting on the 3-month interim results of the Mercury 1 trial, a double-masked, randomized, multicenter, active-controlled, parallel-group 12-month phase 3 study comparing safety and efficacy of a fixed-dose prostaglandin combination with safety and efficacy of each of its components.